Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and congestion in CRSwNP.

The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...

TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo ...

The trial involved symptomatic adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who were treated with standard care but still ... Currently, TEZSPIRE is approved for severe asthma ...

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

Nasal polyps are growths in the nose or sinuses ... Tezspire is currently approved for severe asthma in the US, EU, Japan, and nearly 60 countries. It is approved as a single-use pre-filled ...

The trial involved symptomatic adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP ... Currently, TEZSPIRE is approved for severe asthma treatment in the US, EU, Japan, and ...